Last reviewed · How we verify

Captopril Test Dose and Trandolapril — Competitive Intelligence Brief

Captopril Test Dose and Trandolapril (Captopril Test Dose and Trandolapril) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Angiotensin-converting enzyme (ACE) inhibitors. Area: Metabolic.

marketed Angiotensin-converting enzyme (ACE) inhibitors Angiotensin-converting enzyme (ACE) Metabolic Small molecule Live · refreshed every 30 min

Target snapshot

Captopril Test Dose and Trandolapril (Captopril Test Dose and Trandolapril) — Rigshospitalet, Denmark. Captopril and Trandolapril inhibit the angiotensin-converting enzyme (ACE), reducing the formation of angiotensin II and leading to vasodilation and decreased blood pressure.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Captopril Test Dose and Trandolapril TARGET Captopril Test Dose and Trandolapril Rigshospitalet, Denmark marketed Angiotensin-converting enzyme (ACE) inhibitors Angiotensin-converting enzyme (ACE)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Angiotensin-converting enzyme (ACE) inhibitors class)

  1. Rigshospitalet, Denmark · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Captopril Test Dose and Trandolapril — Competitive Intelligence Brief. https://druglandscape.com/ci/captopril-test-dose-and-trandolapril. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: